Foghorn Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 11, 2026
FHTX$2.04+9.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $80,876 | $55,454 |
| Marketable securities | 78,018 | 188,293 |
| Restricted cash | 1,250 | — |
| Prepaid expenses and other current assets | 3,091 | 5,854 |
| Total current assets | 163,235 | 249,601 |
| Property and equipment, net | 1,915 | 9,964 |
| Restricted cash | 2,000 | 1,708 |
| Other assets | 4 | 68 |
| Operating lease right-of-use assets | 30,949 | 22,641 |
| Total assets | $198,103 | $283,982 |
| Liabilities and Stockholders’ Deficit | ||
| Current liabilities: | ||
| Accounts payable | $4,266 | $3,785 |
| Accrued expenses and other current liabilities | 11,357 | 8,531 |
| Operating lease liabilities | 923 | 9,067 |
| Deferred revenue | 43,192 | 45,606 |
| Total current liabilities | 59,738 | 66,989 |
| Operating lease liabilities, net of current portion | 40,347 | 28,064 |
| Deferred revenue, net of current portion | 205,962 | 234,457 |
| Other liabilities | 556 | — |
| Total liabilities | 306,603 | 329,510 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ deficit: | ||
| Preferred stock, $0.0001 par value; 25,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value; 175,000,000 shares authorized at December 31, 2025 and 2024; 56,657,329 shares issued and outstanding at December 31, 2025 and 55,594,131 shares issued and outstanding at December 31, 2024 | 6 | 6 |
| Additional paid-in capital | 523,937 | 512,515 |
| Accumulated other comprehensive gain | 24 | 135 |
| Accumulated deficit | (632,467) | (558,184) |
| Total stockholders’ deficit | (108,500) | (45,528) |
| Total liabilities and stockholders’ deficit | $198,103 | $283,982 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.